|
Delayed
NSE India S.E.
01:59:24 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 226.57 INR | +14.01% |
|
+18.47% | +31.53% |
| 02:05am | Piramal Pharma Limited, Q2 2027 Earnings Call, Oct 28, 2026 | |
| 10-27 | Piramal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026 | CI |
| Market Cap | 264B 2.78B 2.5B 2.3B 2.09B 3.91B 3.95B 27.63B 10.97B 138B 10.44B 10.22B 439B | P/E 2027 * |
137x | P/E 2028 * | 52.6x |
|---|---|---|---|---|---|
| Enterprise Value | 314B 3.3B 2.96B 2.74B 2.48B 4.64B 4.69B 32.79B 13.02B 164B 12.39B 12.12B 521B | EV / Sales 2027 * |
3.06x | EV / Sales 2028 * | 2.67x |
| Free-Float |
45.44% | Yield 2027 * |
0.08% | Yield 2028 * | 0.2% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| PPLPHARMA | Delayed | |
Bombay S.E.
| PPLPHARMA | Delayed |
Last Transcript: Piramal Pharma Limited
| 1 day | +13.98% | ||
| 1 week | +18.47% | ||
| Current month | +9.68% | ||
| 1 month | +9.64% | ||
| 3 months | +17.10% | ||
| 6 months | +37.72% | ||
| Current year | +31.53% |
| 1 week | 185.02 |  | 228 |
| 1 month | 185.02 | | 228 |
| Current year | 132.3 | | 231.93 |
| 1 year | 132.3 | | 231.93 |
| 3 years | 94.7 | | 307.9 |
| 5 years | 63.1 | | 307.9 |
| 10 years | 63.1 | | 307.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Peter DeYoung
CEO | Chief Executive Officer | 48 | 2020-03-03 |
Brian Guy
PSD | President | - | 2026-10-18 |
Vivek Valsaraj
DFI | Director of Finance/CFO | 53 | 2020-06-09 |
| Director | Title | Age | Since |
|---|---|---|---|
Vivek Valsaraj
BRD | Director/Board Member | 53 | 2022-02-08 |
Peter DeYoung
BRD | Director/Board Member | 48 | 2020-03-03 |
| Chairman | 45 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +14.10% | +18.47% | +12.08% | +137.31% | 2.78B | |
| +0.22% | -0.14% | +55.12% | +128.82% | 1,143B | |
| +0.91% | +3.61% | +41.21% | +84.57% | 647B | |
| -0.12% | -0.93% | +25.59% | +106.14% | 506B | |
| +0.63% | +2.33% | +49.21% | +67.82% | 384B | |
| +0.86% | -4.37% | +61.16% | +37.93% | 350B | |
| +1.02% | +1.80% | +24.84% | +53.75% | 293B | |
| -0.25% | +1.62% | +2.20% | +26.65% | 265B | |
| +0.75% | +2.05% | +53.85% | +71.25% | 242B | |
| +0.25% | +1.64% | +32.05% | +107.62% | 197B | |
| Average | +1.83% | +0.98% | +35.73% | +82.19% | 403.03B | |
| Weighted average by Cap. | +0.45% | +0.71% | +42.23% | +88.49% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 102B 1.08B 968M 894M 810M 1.51B 1.53B 10.71B 4.26B 53.69B 4.05B 3.96B 170B | 117B 1.24B 1.11B 1.02B 928M 1.73B 1.76B 12.27B 4.87B 61.5B 4.64B 4.54B 195B |
| Net income | 1.91B 20.1M 18.04M 16.65M 15.1M 28.23M 28.57M 200M 79.3M 1B 75.43M 73.82M 3.17B | 5.23B 55.11M 49.46M 45.67M 41.41M 77.4M 78.36M 548M 217M 2.74B 207M 202M 8.7B |
| Net Debt | 49.37B 520M 466M 431M 391M 730M 739M 5.16B 2.05B 25.88B 1.95B 1.91B 82.05B | 48.99B 516M 463M 427M 388M 724M 733M 5.12B 2.04B 25.68B 1.94B 1.89B 81.43B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-28 | ₹226.57 | +14.01% | 63,135,018 |
| 26-10-27 | ₹198.72 | +1.82% | 2,873,965 |
| 26-10-26 | ₹195.17 | +2.15% | 1,471,129 |
| 26-10-23 | ₹191.07 | -2.01% | 2,465,513 |
| 26-10-22 | ₹194.99 | +1.99% | 2,835,616 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PPLPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
